Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 17/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 15/20 | 0.61 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.61 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.58 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806463 | 0.86 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL920485 | 0.84 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3155682 | 0.84 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL27598275 | 0.84 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL5367594 | 0.83 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL4669864 | 0.83 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL5367596 | 0.83 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL422889 | 0.83 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL18241088 | 0.83 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL19630972 | 0.83 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017050979-A1 | NANOPARTICLES FOR DIAGNOSIS AND DRUG DELIVERY | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2017-03-30 | — | — | WO | claimed |
| EP-1001946-B1 | QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2010-12-29 | — | — | EP | claimed |
| EP-1951231-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | California Pacific Medical Center (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007048002-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2007-04-26 | — | — | WO | claimed |
| EP-1353673-B1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2007-04-18 | — | — | EP | claimed |
| CN-1553802-A | Camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-12-08 | — | — | CN | claimed |
| US-20040229841-A1 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil | AVENTIS PHARMA S.A. (FR) | 2004-11-18 | — | — | US | claimed |
| US-20040034050-A1 | Homo-camptothecin derivatives | CATHOLIC HEALTHCARE WEST, DOING BUSINESS AS ST. MARY'S MEDICAL CENTER OF SAN FRANCISCO | 2004-02-19 | — | — | US | claimed |
| WO-2003101406-A1 | HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | claimed |
| EP-1353673-A1 | CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002056885-A1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-07-25 | — | — | WO | claimed |
| US-6350756-B1 | USEFUL FOR TREATING CANCER; (20S) ESTERS WITH AN OXYALKANOIC ACID; | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-02-26 | — | — | US | claimed |
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| WO-2021222988-A1 | CELL ENTRY-MODULATING AGENTS AND USES THEREFOR | GRIFFITH UNIVERSITY (AU) | 2021-11-11 | — | — | WO | disclosed |
| EP-2773346-B1 | PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES | TAIWAN LIPOSOME CO LTD (TW) | 2021-10-27 | — | — | EP | disclosed |
| US-10980798-B2 | Pharmaceutical compositions of hydrophobic camptothecin derivatives | TAIWAN LIPOSOME COMPANY, LTD. (TW) | 2021-04-20 | — | — | US | disclosed |
| WO-2000066125-A1 | METHOD FOR TREATING CANCER USING CAMPTOTHECIN DERIVATIVES AND 5-FLUOROURACIL | AVENTIS PHARMA S.A. (FR) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000040529-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000031051-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000007605-A1 | USE OF CAMPTOTHECIN DERIVATIVES, WITH REDUCED GASTROINTESTINAL TOXICITY | AVENTIS PHARMA S.A. (FR) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229841-A1 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil | TOP1, TOP2A, TOP2B | L3MBTL3 3381/4885L3MBTL1 2911/4885MBTD1 3785/4885 |
| US-20040034050-A1 | Homo-camptothecin derivatives | CYP8B1, HCAR3, MTHFD2 | L3MBTL3 1180/4885L3MBTL1 830/4885MBTD1 3047/4885 |
| US-10980798-B2 | Pharmaceutical compositions of hydrophobic camptothecin derivatives | TOP1, TOP2A, TOP2B | L3MBTL3 4269/4885L3MBTL1 3584/4885MBTD1 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.